Inclusion Criteria - Overactive Bladder:

• 18 years of age or older.
• Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation.
• Willing and able to provide signed and dated informed consent.
• Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol.
• Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation.
• For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion).
• For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day.
• *Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject’s condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Inclusion Criteria - Non-Obstructive Urinary Retention:

• 18 years of age or older.
• Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation.
• Willing and able to provide signed and dated informed consent..
• Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol.
• Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation.
• Have a diagnosis of non-obstructive urinary retention as demonstrated by a urinary voiding diary with a minimum of 5 clean intermittent self-catheterizations in a 7-day period; and chronic non-obstructive urinary. retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.
• *Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject’s condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Inclusion Criteria - Fecal Incontinence:

• 18 years of age or older.
• Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation.
• Willing and able to provide signed and dated informed consent.
• Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol.
• Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation.
• Have a diagnosis of fecal incontinence as demonstrated by a bowel diary as greater than or equal to 2 incontinent episodes of more than staining (i.e., either slight, moderate, or severe soiling) per week.
• *Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject’s condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion Criteria - Overactive Bladder:

• Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co‐enrollment in an interventional study is only allowed when documented pre‐approval is obtained from the Medtronic study manager or designee).
• Implanted with a neurostimulator, pacemaker or defibrillator.
• Pelvic floor muscle dysfunction due to surgical intervention or injury.
• Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia).
• History of diabetes unless the diabetes is well‐controlled through diet and/or medications.
• Have symptomatic urinary tract infection (UTI).
• Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component.
• Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study.
• Treatment of symptoms with tibial neuromodulation therapy in the last 3 months.
• Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study.
• Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy.
• Women who are pregnant or planning to become pregnant.
• Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture).
• Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.

Exclusion Criteria - Non-Obstructive Urinary Retention:

• Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co‐enrollment in an interventional study is only allowed when documented pre‐approval is obtained from the Medtronic study manager or designee).
• Implanted with a neurostimulator, pacemaker or defibrillator.
• Pelvic floor muscle dysfunction due to surgical intervention or injury.
• Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia).
• History of diabetes unless the diabetes is well‐controlled through diet and/or medications
• Have symptomatic urinary tract infection (UTI)
• Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
• Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
• Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
• Women who are pregnant or planning to become pregnant
• Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture).
• Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.

Exclusion Criteria - Fecal Incontinence:

• Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co‐enrollment in an interventional study is only allowed when documented pre‐approval is obtained from the Medtronic study manager or designee).
• Implanted with a neurostimulator, pacemaker or defibrillator.
• Pelvic floor muscle dysfunction due to surgical intervention or injury.
• Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia).
• Have uncorrected high grade internal rectal prolapse.
• Treatment of symptoms with tibial neuromodulation therapy in the last 3 months.
• Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study.
• Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy.
• Women who are pregnant or planning to become pregnant.
• Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.

Eligibility last updated 10/22/21. Questions regarding updates should be directed to the study team contact.